Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2009-01-01
Target enrollment:
Participant gender:
Summary
MGCD0103 is an experimental drug that belongs to a class of drugs known as the histone
deacetylase inhibitors, which may restore normal control in cancer cells by affecting the
genes and proteins that are being made. Laboratory tests show that this new investigational
anti-cancer drug can slow down the growth of human cancer cells in mice; two clinical
research studies are currently being performed in humans with cancer and a similar study is
being performed in patients with the same disease.
The purpose of this study is to find out what effect the experimental drug MGCD0103 has on
patients with relapsed and refractory Hodgkin's lymphoma.